StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 2.0 %
TTNP stock opened at $4.90 on Tuesday. The business has a fifty day moving average price of $5.78 and a 200 day moving average price of $6.22. Titan Pharmaceuticals has a fifty-two week low of $4.24 and a fifty-two week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- How to Use the MarketBeat Dividend Calculator
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- About the Markup Calculator
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
